FRESENIUS MEDICAL CARE AG

Fresenius Medical Care drives 6% revenue growth by expanding dialysis services and launching high‑margin diagnostic panels with Quest Diagnostics, positioning itself for sustained leadership in kidney care.

Fresenius Medical Care’s modest share gain reflects a positive outlook: strong EBITDA growth, digital upgrades, and value‑based reimbursement poised to drive future earnings.

Fresenius Medical Care rolls out TherapyWise, a cloud‑based analytics tool boosting ICU KRT efficiency, while a share‑buyback raises EPS and signals confidence.

FMC’s strategy for the expanding global peritoneal dialysis market: how home‑based CAPD growth, evidence‑based safety, and regulatory approvals drive patient outcomes and cost savings.

European markets finish the week on a muted yet positive note as health‑sector gains, especially Fresenius Medical Care’s voting‑rights disclosure, offset geopolitical uncertainties, highlighting the sector’s defensive resilience and investor confid…

Fresenius Medical Care AG shares its 2025 401(k) audit, a 2‑million share buyback, and market outlook, highlighting strong employee benefits and shareholder value creation.

Fresenius Medical Care faces short‑term revenue pressure after EMA recommends revoking TAVNEOS, yet strong margins, cash reserves and a diverse renal portfolio offer resilience amid regulatory uncertainty.

BlackRock’s 7.08 % stake in Fresenius Medical Care highlights how a major asset‑manager can boost FMC’s push toward value‑based dialysis, AI analytics, and home‑care tech for higher margins and better patient outcomes.

Fresenius Medical Care’s modest voting‑rights update shows Artisan Partners’ stake rising to 3.10%. Explore how this shift could influence FMC’s tech roadmap and dialysis market strategy.

German DAX dips yet healthcare stocks, led by Fresenius Medical Care, hold steady—showing resilience amid Europe’s market volatility.